Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind Study Comparing the Safety and Efficacy of Once-Weekly Etanercept 50 mg, Etanercept 25 mg, and Placebo in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis.

Next Previous
X
Search
Trial Profile

A Randomized, Double-Blind Study Comparing the Safety and Efficacy of Once-Weekly Etanercept 50 mg, Etanercept 25 mg, and Placebo in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etanercept (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms PRESERVE
  • Sponsors Pfizer; Wyeth

    • Most Recent Events

    • 11 Jul 2019 Results of post hoc analysis examined the efficacy and safety of the TNF-alpha inhibitor etanercept in elderly versus non-elderly patients with Rheumatoid Arthritis using three studies (T2T, PRESERVE and PRIZE) published in the Drugs and Aging
    • 30 Jun 2019 Results of post hoc analysis published in the Rheumatology
    • 24 Oct 2018 Results of post-hoc analysis assessing the effect of BMI on response to etanercept treatment in patients with rheumatoid arthritis during open-label treatment and following dose reduction or dosing off in patients who achieved low disease activity or remission using data collected from three randomized trials (PRESERVE, N=834; PRIZE, N=306; T2T, N=489), presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top